Developmental and reproductive toxicology (DART) studies play an important role in evaluating how potential therapies may affect fertility, pregnancy, and early-life development. Since different study designs address distinct stages of development and safety questions, selecting the appropriate approach is essential for generating meaningful nonclinical data and meeting regulatory expectations.
In this webinar, Johnathan Furr and AtLee Watson will discuss how different DART study types are selected, the scientific principles behind their design, and key considerations for generating reliable data to support nonclinical safety assessments.
Topics to be covered:
- The role of DART studies in nonclinical safety assessment
- Key differences between the major types of DART studies and when each is appropriate
- Factors that influence study selection and design
- The role of juvenile and multigeneration studies in evaluating developmental risk
- How study design supports regulatory decision-making and efficient drug development
Tuesday, August 18th 2026 | 11:00 AM – 12:30 PM Eastern Time
This webinar will be available to view live and on demand.
Speakers
Johnathan Furr
Director, Developmental and Reproductive Toxicology
Inotiv
AtLee Watson, PhD
Director, In Vivo Operations
Inotiv
